Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly

This is more a distribution-channel fight than a product-data fight. In obesity, the first 1-3 prescriptions are heavily influenced by consumer pull-through and physician shorthand, so a successful challenge to comparative ads could matter more for near-term script momentum than for long-run efficacy rankings. That favors NVO at the margin because the new higher-dose Wegovy label weakens the clean superiority narrative Lilly has been using to defend share.

The key catalyst is not the filing itself but whether a court is willing to move quickly on a preliminary injunction. If the ads stay up, the market will likely shrug this off as noise; if they come down or require corrective messaging, Lilly loses a low-cost demand-generation lever just as obesity competition is normalizing and payers are tightening prior auth. Over 6-18 months, the real risk for both names is that the category shifts from marketing-led growth to access-led growth, where incremental share is harder to buy with DTC spend.

Consensus is probably overestimating how durable Lilly’s consumer brand advantage is and underestimating how much of that advantage came from messaging asymmetry rather than a permanent clinical moat. The contrarian view is that this could be a modest positive for NVO even if the lawsuit never reaches trial: the mere threat of injunction may force Lilly to de-emphasize comparative claims, narrowing the perception gap before any substantive prescription data changes. The main falsifier is simple: if there is no PI and no measurable share loss in US obesity scripts over the next quarter, this becomes a legal sideshow rather than a fundamental catalyst.